Singapore, June 26 -- CStone Pharmaceuticals, a China-based biopharmaceutical company, has entered into an exclusive commercialisation agreement with Arrotex Pharmaceuticals, a core pharmaceutical commercialisation platform of DBG Health, Australia's largest diversified healthcare group, for the commercialisation of sugemalimab in Australia and New Zealand.

Under the terms of the agreement, CStone will receive an upfront payment from Arrotex and is eligible for additional regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

Arrotex will hold exclusive commercialisation rights for sugemalimab in Australia and New Zealand across all approved and future indication...